Artificial Heart Market By By Product Type (Total Artificial Heart, Ventricular Assist Devices {Left Ventricular Assist Devices, Right Ventricular Assist Devices, Bi-Ventricular Assist Devices}), By Technology (Pneumatic Artificial Heart, Electro-hydraulic Artificial Heart, Magnetic Levitation Artificial Heart), By Application (Bridge to Transplant, Destination Therapy, Others), By End-User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Research Institutes, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

What trends will shape the Artificial Heart Market in the coming years?

The Artificial Heart Market accounted for USD 3.56 Billion in 2024 and USD 3.98 Billion in 2025 is expected to reach USD 12.1 Billion by 2035, growing at a CAGR of around 11.8% between 2025 and 2035. The Artificial Heart Market is associated with devices such as ventricular assistance devices (VADs), total artificial hearts (TAHs) that are used to mechanically support the failing human heart or replace the heart completely, thus the artificial heart market acts as a bridge to transplantation.

The related innovation trends are miniaturized, biocompatible devices based on developing sensor integration, AI-based flows, magnetic levitation pumps, and remote-monitoring systems. Changes in regulation and expedited trial programs are already facilitating the introduction of next-gen TAHs, but cost and reimbursement issues also make their uptake difficult. Considering the future, the immense potential exists in personalized treatment in the form of patient-specific implants through 3d printing, patient digital twin monitoring, and truly implantable and long-term artificial hearts. 

What do industry experts say about the Artificial Heart Market trends?

"The Total Artificial Heart represents a critical bridge to transplant for patients with end-stage biventricular heart failure. While challenges remain in long-term durability and infection prevention, advancements in biomaterials and pump design are steadily improving outcomes."

• Dr. Robert Kormo, Medical Director of Mechanical Circulatory Support, Abbott

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Artificial Heart Market?

How is the rising prevalence of heart failure boosting market growth?

A major factor driving the Artificial Heart Market is the skyrocketing prevalence of heart failure worldwide. Heart failure has become a leading cause of death, affecting millions of people with severe cardiac conditions and necessitating advanced treatments. The rising incidence of lifestyle diseases, obesity, and hypertension further escalates the risk of heart failure. Traditional treatments like medications and surgical procedures often fail for end-stage patients, boosting the demand for mechanical circulatory support devices.

Notably, over 2,000 Total Artificial Hearts (TAH) have been implanted globally since the first successful implantation in 1982, with the SynCardia Temporary Total Artificial Heart (TAH) alone accounting for more than 1,900 implants worldwide. The increasing use of artificial hearts, particularly TAH and Ventricular Assist Devices (VADs), is emerging as a life-saving solution for such patients. Moreover, with the global population ageing, the number of individuals vulnerable to cardiac diseases continues to rise, making the need for artificial hearts long-term and persistent. Improved cardiac care infrastructure from governments and healthcare providers further supports the market’s expansion in the coming years.

Why is the shortage of heart donors driving artificial heart demand?

One of the major drivers behind the Artificial Heart Market is the desperate demand for donor hearts worldwide. Heart transplantation remains the gold standard for advanced heart failure; however, the availability of suitable donor organs is critically scarce. An estimated 26 million people globally suffer from heart failure (American Heart Association), yet many patients remain on long waiting lists, with some dying before a transplant becomes available. This urgent need for alternatives has accelerated the adoption of artificial hearts, which can serve as either temporary or permanent solutions for patients awaiting transplants.

Ventricular Assist Devices (VADs) are widely used as bridge-to-transplant solutions to stabilize patients until donor organs become available. Furthermore, advancements in the lifespan and performance of these devices are positioning artificial hearts as viable long-term treatment options. As this gap between organ supply and demand widens on a global scale, there is increasing pressure for innovative cardiac support solutions, fuelling robust growth in the Artificial Heart Market.

How does the high cost of artificial heart devices limit market expansion?

A major obstacle that has limited the expansion of the Artificial Heart Market is the fact that the cost of acquiring artificial heart devices and the closely related procedures is high. Such devices, especially Total Artificial Hearts and advanced Ventricular Assist Devices, engage in complicated engineering, rigorous clinical trials, and an increase in the cost of production. Also, surgical implantation costs, other financial costs of post-op life, and the patient in need of long-term maintenance during this surgery all add to the total financial load.

These costs are unaffordable by most patients in most regions, particularly the developing economies, even in the case where the insurance cover is partial. In addition, restricted reimbursement and the fact that it is expensive to have it out of pocket by the patient also keep away its mass implemented in various healthcare systems. The cost factor not only restricts the access of patients but also makes healthcare providers less likely to use such technologies. Consequently, issues of cost continue to pose huge limitations to the growth potential of the Artificial Heart Market across the world.

How can emerging markets enhance growth for artificial heart solutions?

The latter is an action-packed healthcare development in developing markets, creating great interest in the Artificial Heart Market. Asian-Pacific countries, Latin America, and the Middle East countries are spending huge sums to enhance their health infrastructure, including the use of modern cardiac treatment technology. Advancing cases of cardiovascular afflictions, an upsurge in awareness of health, and the expansion of middle-class demographics are some of the issues that are causing demand for life-saving treatments, such as artificial heart systems.

Besides, governments in these areas are initiating schemes to enhance cardiac care accessibility as well as promoting partnerships with companies dealing with medical devices. These good situations are causing emerging markets to be favorable destinations for artificial heart manufacturers wishing to expand outside of the traditional markets like North America and Europe. Since affordability is increasing, and the healthcare infrastructure is being put in place, the Artificial Heart Market is set to have an advantage in that there would be more penetration of devices and new markets in these high-potential markets.

Why does 3D printing technology create new product development opportunities?

The progress in 3D printing is one of the changes that generate transfiguring possibilities in the Artificial Heart Market. 3D printing technology allows the creation of customizable cardiac implants that fit anatomically, enhancing the performance of the implants and the surgical results. Through the innovative designs and biocompatible materials, the artificial heart can be manufactured using customizable materials as well as fit every patient's individual needs. The prototyping and testing process is also faster, shortening development time and cost with this technology.

Moreover, 3D printing creates new opportunities related to making complicated parts of devices that can hardly be made by the classical approach. Future detailed creation potential has also been proposed in bio-printed tissues work and heart personalized parts research, as well as whole-person-customized artificial hearts. With 3D printing getting more sophisticated and readily available, it will lead to a revolution in product development in the Artificial Heart Market, where companies will introduce more effective, more customized, and cheaper products to serve the heart failure community.

What are the key market segments in the Artificial Heart industry?

Based on the Product Type, the Artificial Heart Market has been classified into Total Artificial Heart (TAH) and Ventricular Assist Devices (VADs), comprising Left Ventricular Assist Devices (LVADs), Right Ventricular Assist Devices (RVADs), and Bi-Ventricular Assist Devices (BiVADs). Among them, the LVAD market is dominant because it has a high success rate and is widely used to treat severely affected left-sided ventricular patients.

LVADs have become a common bridge-to-transplant tool as well as a destination therapy, thus making them the sought-after treatment by medical services. Miniaturization and LVADs having long-term durability are all on the rise and are soon to increase the demand for such devices in the Artificial Heart Market across the world.

Based on the Technology, the Artificial Heart Market has been classified into Pneumatic Artificial Heart, Electro-hydraulic Artificial Heart, and Magnetic Levitation Artificial Heart. The most powerful segment at present is the Magnetic Levitation Artificial Hearts due to their excellent efficiency, lesser wear and tear, and the possibility of fewer complications like blood clots.

The use of moving parts in these devices is suspended, and these devices experience less friction due to the magnetic fields used. They have proven to be very popular both with the surgeons and the patients due to their ability to offer constant blood flow with comparatively few mechanical problems. Since the market is increasing to find for long-term solutions, the magnetic levitation technology is advancing towards establishing a better presence in the market.

Which regions are leading the Artificial Heart Market, and why?

The North America Artificial Heart Market has covered the biggest share, which is mainly explained by sufficient infrastructure in the sphere of healthcare provision, the vast amount of healthcare expenditures, and the popularity of innovative technologies in the sphere of cardiac care. The prevalence of heart failure and cardiovascular diseases is high in the region, and this is forcing intense demand for artificial heart products, including LVAD and TAH.

Besides, the North American market is further boosted by the availability of major manufacturers of medical devices, the presence of reimbursement policy, and the extensive clinical-related research. The U.S. is at the forefront of this development, and it has already embraced novel cardiac applications and government programs toward enhanced heart therapy. This is the probable heavy regional dominance that should exist in the Artificial Heart Market in the future.

Asia-Pacific Artificial Heart Market is the region that is going to grow at the fastest rate due to increased incidences of heart diseases and the rapid growth of healthcare facilities available very quickly. The growth in investment in healthcare and the rising information regarding the advanced forms of treatment of heart failure contribute to stimulating the use of artificial heart technologies in China, India, Japan, and South Korea.

Also, the increase in the number of people in the middle-class sector and the rise in the sector of medical tourism foster a market. Regional demand is further enhanced by the fact that the government is making concerted efforts to improve cardiac care, as well as partnerships with international medical device companies. With the increase in accessibility, the Asia-Pacific region is expected to experience a high growth rate and considerable market extent of the Artificial Heart Market.  

What does the competitive landscape of the Artificial Heart Market look like?

The artificial heart market can be said to be highly competitive in terms of the level of innovation characteristics evident in the market, and also strategic alliances, as the key players in the market strive to increase their market share. To enhance patient outcomes and decrease the chances of post-implantation complications, companies are targeting the development of technologically advanced, durable, and miniaturized devices. Major contenders in this market are Abbott Laboratories, Medtronic, SynCardia Systems, Carmat, Jarvik Heart, BiVACOR, Evaheart, as well as Berlin Heart, Abiomed (a Johnson & Johnson venture), and ReliantHeart. These corporations are also actively involved in the launch of products, regulatory approvals, and trials, and in agreements with healthcare providers and research institutions.

Lots of players are pouring high investments in R&D in see-through codification devices that have acquired magnetic floating and sensor-based monitoring technologies. Moreover, hospital-based joint clinical research and clinical assessment during training are also the usual practices. Other opportunities in the emerging markets are also being ventured by the companies in terms of distribution agreements and joint ventures to expand their global coverage. This competitive setting has led to a continuous improvement in the artificial heart market, both in terms of accessibility and performance in terms of this life-saving device.

Artificial Heart Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Artificial Heart industry?

• In June 2024, Carmat announced the first successful implantation of its Aeson artificial heart in the United States as part of its EFICAS clinical study. The groundbreaking procedure was performed at Duke University Hospital, marking a significant milestone for Carmat’s U.S. expansion efforts.
• In April 2024, SynCardia announced that it had received FDA approval for an updated driver system for its 70cc Temporary Total Artificial Heart (TAH). This newly approved driver system is designed to enhance patient mobility and improve the overall quality of life during treatment.

Report Coverage:

By Product Type

• Total Artificial Heart
• Ventricular Assist Devices
  • Left Ventricular Assist Devices
  • Right Ventricular Assist Devices
  • Bi-Ventricular Assist Devices

By Technology

• Pneumatic Artificial Heart
• Electro-hydraulic Artificial Heart
• Magnetic Levitation Artificial Heart

By Application

• Bridge to Transplant
• Destination Therapy
• Others

By End-User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Research Institutes
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• SynCardia Systems LLC
• Abbott Laboratories
• Medtronic plc
• Jarvik Heart, Inc.
• Carmat SA
• BiVACOR Inc.
• Evaheart, Inc.
• ReliantHeart Inc.
• Berlin Heart GmbH
• Abiomed, Inc.
• Calon Cardio-Technology Ltd
• FineHeart SA
• CorWave SA
• CH Biomedical, Inc.
• Cirtec Medical Systems

Frequently Asked Questions (FAQs)